Clue, known for its period tracking app used by ~13M, gets FDA clearance to debut a digital contraceptive that gives users a statistical prediction of ovulation
Context & Ripple Effects
Clue's clearance is the payoff of a decade-long arc that began when it raised $7M in 2015 explicitly to build a female-health platform beyond cycle logging, then a $20M Series B led by Nokia Growth Partners to fund it. The company now converts its ~13M-user tracking base into a regulated medical product.
It also enters a market Natural Cycles already validated: the Swedish app won FDA clearance first and has since scaled to ~3M users on the strength of a $55M Series C in 2024 that took its total funding past $95M, following its earlier $30M Series B.
First-order effects
- Clue's ~13M users gain access to an FDA-cleared statistical ovulation-prediction contraceptive inside an app they already use daily, turning a free tracking habit into a regulated birth-control option.
- Natural Cycles loses its position as the only FDA-cleared digital contraceptive of scale, facing a rival whose user base is more than four times its own.
Second-order effects
- Natural Cycles' investor case now rests on clinical differentiation and international expansion rather than regulatory exclusivity, pressuring it to justify its $95M+ raise against a competitor that reached clearance without comparable dedicated capital.
- Other period-tracking apps face a fork: pursue their own FDA clearances or remain consumer-wellness products while the regulated tier captures users willing to pay for contraception.
Third-order effects
- If Clue's conversion holds, femtech consolidates into two tiers — cleared medical devices with pricing power and uncleared trackers competing on engagement — with FDA clearance becoming the primary moat rather than user counts.
- The pattern extends the FDA's broader posture toward software-as-medical-device, from wearables detecting sleep apnea and pulse loss to reproductive health apps, normalizing algorithmic predictions as prescription-adjacent contraception.
The trend: Cycle-tracking apps are graduating from wellness logging to FDA-cleared medical devices, with regulatory clearance replacing network size as the category's defining asset.